164 related articles for article (PubMed ID: 20692295)
21. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
Chaix ML; Descamps D; Wirden M; Bocket L; Delaugerre C; Tamalet C; Schneider V; Izopet J; Masquelier B; Rouzioux C; Meyer L; Costagliola D; ; ;
AIDS; 2009 Mar; 23(6):717-24. PubMed ID: 19279445
[TBL] [Abstract][Full Text] [Related]
22. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
Bracciale L; Colafigli M; Zazzi M; Corsi P; Meraviglia P; Micheli V; Maserati R; Gianotti N; Penco G; Setti M; Di Giambenedetto S; Butini L; Vivarelli A; Trezzi M; De Luca A
J Antimicrob Chemother; 2009 Sep; 64(3):607-15. PubMed ID: 19608581
[TBL] [Abstract][Full Text] [Related]
24. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
25. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
[TBL] [Abstract][Full Text] [Related]
26. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
Chiappini E; Galli L; Zazzi M; de Martino M
J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
[TBL] [Abstract][Full Text] [Related]
27. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
28. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
[TBL] [Abstract][Full Text] [Related]
29. Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008.
Stańczak GP; Stańczak JJ; Marczyńska M; Firlag-Burkacka E; Wiercińska-Drapało A; Leszczyszyn-Pynka M; Jabłonowska E; Małolepsza E; Dyda T; Zabek P; Horban A
J Med Virol; 2010 Jul; 82(7):1291-4. PubMed ID: 20513098
[TBL] [Abstract][Full Text] [Related]
30. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
Pillay D
Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
[TBL] [Abstract][Full Text] [Related]
31. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
[TBL] [Abstract][Full Text] [Related]
33. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals.
Torti C; Bono L; Gargiulo F; Uccelli MC; Quiros-Roldan E; Patroni A; Paraninfo G; Tirelli V; Manca N; De Francesco MA; Perandin F; Carosi G
Clin Microbiol Infect; 2004 Sep; 10(9):826-30. PubMed ID: 15355414
[TBL] [Abstract][Full Text] [Related]
35. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance.
Truong HM; Grant RM; McFarland W; Kellogg T; Kent C; Louie B; Wong E; Klausner JD
AIDS; 2006 Nov; 20(17):2193-7. PubMed ID: 17086059
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
Soriano V
Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
[TBL] [Abstract][Full Text] [Related]
37. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece.
Paraskevis D; Magiorkinis E; Katsoulidou A; Hatzitheodorou E; Antoniadou A; Papadopoulos A; Poulakou G; Paparizos V; Botsi C; Stavrianeas N; Lelekis M; Chini M; Gargalianos P; Magafas N; Lazanas M; Chryssos G; Petrikkos G; Panos G; Kordossis T; Theodoridou M; Sypsa V; Hatzakis A;
Virus Res; 2005 Sep; 112(1-2):115-22. PubMed ID: 16022906
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection.
Biagetti C; Bon I; Vitone F; Schiavone P; Borderi M; Pavoni M; Verucchi G; Re MC; Chiodo F
New Microbiol; 2009 Apr; 32(2):129-34. PubMed ID: 19579688
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of transmitted HIV-1 drug resistance among female sex workers and men who have sex with men in El Salvador, Central America.
Murillo W; Lorenzana de Rivera I; Albert J; Guardado ME; Nieto AI; Paz-Bailey G
J Med Virol; 2012 Oct; 84(10):1514-21. PubMed ID: 22930496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
